The stock of Regulus Therapeutics Inc (NASDAQ:RGLS) is a huge mover today! About 422,766 shares traded hands. Regulus Therapeutics Inc (NASDAQ:RGLS) has declined 61.17% since April 13, 2016 and is downtrending. It has underperformed by 65.10% the S&P500.
The move comes after 8 months negative chart setup for the $179.54 million company. It was reported on Nov, 15 by Barchart.com. We have $2.61 PT which if reached, will make NASDAQ:RGLS worth $21.54 million less.
Regulus Therapeutics Inc (NASDAQ:RGLS) Ratings Coverage
Out of 5 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Regulus Therapeutics has been the topic of 10 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The rating was downgraded by BMO Capital Markets on Tuesday, June 28 to “Market Perform”. Chardan Capital Markets maintained it with “Buy” rating and $13.50 target price in Tuesday, June 28 report. Chardan Capital Markets initiated Regulus Therapeutics Inc (NASDAQ:RGLS) on Wednesday, April 13 with “Buy” rating. Wedbush maintained Regulus Therapeutics Inc (NASDAQ:RGLS) on Wednesday, August 5 with “Buy” rating. The stock of Regulus Therapeutics Inc (NASDAQ:RGLS) has “Buy” rating given on Tuesday, June 7 by Chardan Capital Markets. Needham maintained Regulus Therapeutics Inc (NASDAQ:RGLS) rating on Tuesday, June 28. Needham has “Buy” rating and $10 price target. The rating was initiated by Wells Fargo with “Outperform” on Friday, December 4. The stock of Regulus Therapeutics Inc (NASDAQ:RGLS) has “Buy” rating given on Wednesday, November 2 by Needham. BMO Capital Markets initiated the shares of RGLS in a report on Tuesday, April 12 with “Outperform” rating.
According to Zacks Investment Research, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.”
Insitutional Activity: The institutional sentiment increased to 1.23 in Q2 2016. Its up 0.19, from 1.04 in 2016Q1. The ratio is positive, as 26 funds sold all Regulus Therapeutics Inc shares owned while 14 reduced positions. 6 funds bought stakes while 43 increased positions. They now own 27.05 million shares or 18.99% less from 33.39 million shares in 2016Q1.
Teachers Retirement Sys Of The State Of Kentucky has 0% invested in the company for 108,900 shares. Blackrock Institutional Na last reported 751,661 shares in the company. Fmr Lc owns 7.92 million shares or 0% of their US portfolio. Kcg Holdings holds 80,941 shares or 0% of its portfolio. Deutsche Natl Bank Ag last reported 0% of its portfolio in the stock. Bnp Paribas Arbitrage Sa reported 1,508 shares or 0% of all its holdings. Piermont, a Missouri-based fund reported 151,924 shares. American Group Inc last reported 0% of its portfolio in the stock. Blackrock accumulated 2,959 shares or 0% of the stock. Teacher Retirement Sys Of Texas holds 4,371 shares or 0% of its portfolio. Citadel Limited Liability has invested 0% of its portfolio in Regulus Therapeutics Inc (NASDAQ:RGLS). Cubist Systematic Strategies Limited Com holds 0% or 11,924 shares in its portfolio. Globeflex Ltd Partnership accumulated 80,637 shares or 0.06% of the stock. State Street last reported 551,539 shares in the company. Blackrock Investment Mgmt holds 0% or 148,444 shares in its portfolio.
More news for Regulus Therapeutics Inc (NASDAQ:RGLS) were recently published by: Fool.com, which released: “Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?” on June 28, 2016. Fool.com‘s article titled: “Why Regulus Therapeutics Inc. Fell 20.1% in April” and published on May 10, 2016 is yet another important article.
RGLS Company Profile
Regulus Therapeutics Inc., incorporated on September 5, 2007, is a biopharmaceutical firm focused on discovering and developing drugs that target microribonucleic acid (microRNAs) to treat a range of diseases. The Firm uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical firm to explore microRNAs as biomarkers for specific patient populations.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.